The Phase 1 initiation of STX-1150 and CIRM grants de-risk the pipeline, while the IPO cash runway removes near-term financing overhang. Traders should watch for initial STX-1150 clinical data in H1 2027 as the primary catalyst; the stock's strong historical momentum suggests continued upside on pipeline progress.
Price Chart
Executive Summary
Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9M (down 61% YoY from $4.9M) and a net loss of $6.5M ($2.62/share), narrower than the $9.9M loss in Q2 2025. The company initiated the Phase 1 trial of STX-1150 (LDL-C lowering) and secured ~$25.7M in CIRM grants for STX-1200 and STX-1400. The July 2026 IPO and Sanofi private placement raised ~$140.6M net, extending cash runway into H1 2029.
Key Financial Metrics
Key Facts
- Initiated first-in-human Phase 1 trial of STX-1150 (LDL-C lowering) in Australia; initial clinical data expected H1 2027.
- Awarded ~$25.7M in non-dilutive CIRM grants for STX-1200 (Lp(a)) and STX-1400 (triglycerides).
- Completed upsized IPO and Sanofi private placement, generating ~$155.5M gross proceeds (~$140.6M net).
- Cash, cash equivalents, and marketable securities of $43.0M as of June 30, 2026, plus IPO net proceeds provide funding into H1 2029.
- Collaboration revenue fell to $1.9M from $4.9M YoY; net loss narrowed to $6.5M from $9.9M.
- Preclinical data for STX-1150 showed up to 68% LDL-C reduction in NHPs, sustained for two years.
Financial Impact
Net loss of $6.5M on $1.9M revenue; cash position of $43.0M plus ~$140.6M IPO net proceeds provides runway into H1 2029.
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; revenue decline from collaboration agreements.
- Phase 1 data for STX-1150 is not expected until H1 2027, leaving a long catalyst gap.
- Dilution from IPO and private placement; net loss and negative stockholders' deficit of $164.8M.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3355504 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.60 (−49.37%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.60 (−49.37%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.60 (−23.53%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.60 (−23.53%) |
Jul 28, 2026 12w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $15.60 (−15.03%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $15.60 (−17.76%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.60 (−27.94%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.60 (−27.94%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers